Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367663 | 0.82 | ABL1 (0.57) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL9543202 | 0.79 | BACE1 (0.57) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL9542420 | 0.79 | ABL1 (0.55) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL9543525 | 0.77 | ABL1 (0.59) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL24223835 | 0.76 | SHMT2 (0.38) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL19236889 | 0.76 | SHMT2 (0.45) | KMT2AXDHKDM4EHSD17B10 | |
| SCHEMBL10981661 | 0.76 | ABL1 (0.51) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL10987552 | 0.75 | ABL1 (0.48) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL12820949 | 0.75 | ABL1 (0.48) | ABL1RIN1CYP3A4BLMKMT2A | |
| SCHEMBL17422233 | 0.73 | POLB (0.50) | KMT2AXDHKDM4ECYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| WO-2011035009-A1 | HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-1993020075-A1 | 8-SUBSTITUTED-N5-DEAZAPTERINS AS ANTIFOLATES | THE UNIVERSITY OF SYDNEY (AU) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | ABL1 2486/4885RIN1 110/4885CYP3A4 4725/4885 |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | GGH, GGPS1, GGT1 | ABL1 3418/4885RIN1 1701/4885CYP3A4 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.